These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36077857)

  • 1. Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer.
    Park CS; Sung MJ; Kim SJ; Jo JH; Lee HS; Chung MJ; Bang S; Park SW; Song SY; Park JY
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study.
    Lee SH; Lee HS; Lee SH; Woo SM; Kim DU; Bang S
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response.
    Kang J; Jeong JH; Hwang HS; Lee SS; Park DH; Oh DW; Song TJ; Kim KH; Hwang S; Hwang DW; Kim SC; Park JH; Hong SM; Kim KP; Ryoo BY; Yoo C
    Cancer Res Treat; 2020 Apr; 52(2):594-603. PubMed ID: 32019287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
    Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I
    Oncologist; 2018 Dec; 23(12):1407-e136. PubMed ID: 29853658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
    Agarwal R; Sendilnathan A; Siddiqi NI; Gulati S; Ghose A; Xie C; Olowokure OO
    J Gastrointest Oncol; 2016 Dec; 7(6):996-1003. PubMed ID: 28078124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
    Goktas Aydin S; Cakan Demirel B; Bilici A; Topcu A; Aykan MB; Kahraman S; Akbıyık I; Atci MM; Olmez OF; Yaren A; Sendur MAN; Geredeli C; Seker M; Urun Y; Karadurmus N; Aydin A
    Curr Med Res Opin; 2022 Oct; 38(10):1751-1758. PubMed ID: 35916475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.
    Kim H; Kim R; Jo H; Kim HR; Hong J; Ha SY; Park JO; Kim ST
    Therap Adv Gastroenterol; 2022; 15():17562848221117638. PubMed ID: 35992188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
    Ksienski D; Wai ES; Alex D; Croteau NS; Freeman AT; Chan A; Patterson T; Clarkson M; Fiorino L; Poonja Z; Fenton D; Irons S; Lesperance M
    Transl Lung Cancer Res; 2021 Jan; 10(1):355-367. PubMed ID: 33569318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
    Torasawa M; Yoshida T; Yagishita S; Shimoda Y; Shirasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Lung Cancer; 2022 May; 167():49-57. PubMed ID: 35397298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
    Liao J; Liu C; Long Q; Wu X; Wang H; Yu H; Sun S; Zhang Y; Lin Y; Zhao X; Wang J
    Front Oncol; 2021; 11():752545. PubMed ID: 34660317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
    Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
    Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
    Ogul A; Kidi MM; Buyuksimsek M
    J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
    McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
    Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
    Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
    Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
    Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
    Stares M; Ding TE; Stratton C; Thomson F; Baxter M; Cagney H; Cumming K; Swan A; Ross F; Barrie C; Maclennan K; Campbell S; Evans T; Tufail A; Harrow S; Lord H; Laird B; MacKean M; Phillips I
    ESMO Open; 2022 Apr; 7(2):100445. PubMed ID: 35398717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.